Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

被引:17
|
作者
Papeix, C. [1 ]
Donze, C. [2 ]
Lebrun-Frenay, C. [3 ]
机构
[1] Sorbonne Univ, Hop Pitie Salpetriere, AP HP 6, Dept Neurol,CRCSEP Paris, F-75013 Paris, France
[2] Hop St Philibert, Fac Med & Maleut Lille, Grp Hop Inst Catholique Lille, Lomme Les Lille, France
[3] Cote dAzur Univ, URC2A, CRCSEP Cote dAzur, Neurol,Hop Pasteur2,CHU Nice, Nice, France
关键词
Multiple sclerosis; Infections; Prevention; Immuno-active treatment; PLACEBO-CONTROLLED TRIAL; EPSTEIN-BARR-VIRUS; DOUBLE-BLIND; INTERFERON BETA-1A; VIRAL-INFECTIONS; OPEN-LABEL; INTRAMUSCULAR INTERFERON; ORAL TERIFLUNOMIDE; GLATIRAMER ACETATE; CONTROLLED PHASE-3;
D O I
10.1016/j.neurol.2021.04.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. - Viral, bacterial, or fungal infections are suspected of triggering multiple sclerosis (MS) and promoting relapses of the disease and are likely to be promoted by immune-active treatments. This raises questions about the infectious workup and preventive treatment of these infections prior to their initiation. Objectives. - To establish recommendations on infections and MS. Provide information to patients and healthcare professionals on the minimal infectious workup to be performed in an MS patient at diagnosis and prior to initiation of immuno- active therapy in MS. Methods. - The recommendation attempts to answer four main questions about infections and MS. The French Group for Recommendations in Multiple Sclerosis (France4MS) did a systematic review of articles from PubMed and universities databases (from January 1975 to June 2020), using the RAND/UCLA formalized consensus method. The RAND/UCLA method has been developed to synthesize the scientific literature and expert opinions on health care topics and was used for reaching a formal agreement. Twenty-three experts contributed to the detailed review and a group of 63 multidisciplinary health professionals validated the final version of 36 recommendations. Results. - It is recommended that MS patients undergo a minimal infectious workup, check their vaccination status at diagnosis, and repeat it during follow-up and before starting immunotherapy. Screening and preventive treatment of viral (group Herpes virus, HPV, JCV, HCV, HBV), bacterial (mycobacteria) and fungal (Cryptococcus) infections is recommended prior to the initiation of certain immuno-active MS therapies. Discussion and conclusions. - At diagnosis of MS and prior to the choice of therapeutic strategy, it is recommended to update the vaccination schedule of MS patients in reference to the HCSP vaccination schedule and the SFSEP recommendations. Before starting immunosuppressive treatment, it is recommended to inform patients of the risks of infections and to look for a constitutive or acquired immune deficiency. Health professionals and patients should be informed of the updated recommendations on infections and MS. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:980 / 994
页数:15
相关论文
共 50 条
  • [31] Multiple Sclerosis
    Yamasaki, Ryo
    Kira, Jun-ichi
    MYELIN: BASIC AND CLINICAL ADVANCES, 2019, 1190 : 217 - 247
  • [32] Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016
    Garcia Merino, A.
    Ara Callizo, J. R.
    Fernandez Fernandez, O.
    Landete Pascual, L.
    Moral Torres, E.
    Rodriguez-Antigueedad Zarrantz, A.
    NEUROLOGIA, 2017, 32 (02): : 113 - 119
  • [33] CONTEMPORARY TREATMENT OPTIONS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Salhofer-Polanyi, S.
    Leutmezer, F.
    DRUGS OF TODAY, 2014, 50 (05) : 365 - 383
  • [34] Multiple Sclerosis and Vitamin D: A Review and Recommendations
    Andrew J. Solomon
    Ruth H. Whitham
    Current Neurology and Neuroscience Reports, 2010, 10 : 389 - 396
  • [35] Drug therapy for multiple sclerosis
    Tavazzi, Eleonora
    Rovaris, Marco
    La Mantia, Loredana
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (11) : 833 - 840
  • [36] Daclizumab Treatment for Multiple Sclerosis
    Kim, Sylvia E.
    PHARMACOTHERAPY, 2009, 29 (02): : 227 - 235
  • [37] Diagnosis and treatment of multiple sclerosis
    Zavalishin, I. A.
    Peresedova, A. V.
    Stoida, N. I.
    Gur'yanova, O. E.
    Arzumanyan, N. Sh
    Alekseeva, N. S.
    Eliseeva, D. D.
    Gulevskaya, T. S.
    Bryukhov, V. V.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2011, 111 (06) : 89 - 96
  • [38] The Emerging Role of Neutrophil Granulocytes in Multiple Sclerosis
    Woodberry, Tonia
    Bouffler, Sophie E.
    Wilson, Alicia S.
    Buckland, Rebecca L.
    Bruestle, Anne
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [39] Evolving concepts in the treatment of relapsing multiple sclerosis
    Comi, Giancarlo
    Radaelli, Marta
    Sorensen, Per Soelberg
    LANCET, 2017, 389 (10076) : 1347 - 1356
  • [40] Emerging therapies for multiple sclerosis
    de Lorenzo-Pinto, Ana
    Guadalupe Rodriguez-Gonzalez, Carmen
    Ais-Larisgoitia, Arantza
    MEDICINA CLINICA, 2013, 140 (02): : 76 - 82